SELLAS Life Sciences Group, Inc. — Director's Dealing 2015

Dec 30, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2015-10-30

Reporting Person: Nejadnik Bijan (Executive VP and CMO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-10-30	Stock Option (right to buy)	$1.68	A	350000	Acquired	2025-10-30	Common Stock (350000)	Direct

Footnotes

F1: Granted pursuant to the Issuer's Amended and Restated 2007 Incentive Plan.

F2: The stock option will vest in 16 equal, quarterly installments over 4 years beginning 3 months from the date of grant, as long as the Reporting Person remains in the Issuer's continuous employ through the vesting period.